Accelr8 Presents Two Studies at ASM 2012 and Receives Acceptance to Present a New Blood Study

Accelr8 Technology Corporation AXK announced results of two studies that it presented at the 112th annual General Meeting of the American Society for Microbiology (www.asm.org). The first study used the company's BACcel™ rapid automated diagnostic system with positive blood cultures to detect a major, complex multi-drug resistance expression type known as “ESBL.” The system's 3-hour results showed the benefits of the platform decreasing time to result by 1-2 days over the best standard method while maintaining 100% sensitivity and 94% specificity. ESBL resistance has spread globally with hundreds of molecular variants. Early ESBL spread occurred in hospitals, but is now reaching into community-acquired infections. These resistance types are difficult to detect and severely reduce treatment options in the largest family of Gram-negative pathogens.